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LETTERS TO THE EDITOR
Neutrophil activation and
renal scarring
To the Editor: In their recently published manuscript,
Svensson et al present data that implicates dysfunctional
neutrophil responses in the initiation of renal scarring [1].
Using IL-8 receptor-deficient mice they have elegantly
shown that the disruption of neutrophil trafficking results
in prolongation of infection, abscess formation, retention
of neutrophils within the inflamed tissue, and eventually
progressive renal scarring. These are important findings
as they begin to address the central question of individ-
ual susceptibility to urinary tract infection, and provide a
mechanistic interpretation for findings of potential IL-8
receptor deficiency states in humans [2].
What these authors fail to acknowledge is that as early
as 1988 we proposed that aberrant activation of neu-
trophil respiratory burst activation and degranulation by
type I fimbriate uropathogenic Escherichia coli was a
key factor in the genesis of renal scarring [3, 4]. While
the model chosen would seem to have some advantages
over previous ones of ascending infection or direct injec-
tion, what the current study fails to address in these com-
promised animals is the relative importance of bacterial
virulence versus host susceptibility in contributing to uri-
nary tract infection (UTI) and renal scarring. These au-
thors have long acknowledged and published widely on
the importance of P-fimbriae in ascending infection and,
although initially skeptical [5, 6] despite the demonstra-
tion of their expression in vivo [7], have lately accepted
(without ever citing our work) the important virulence
enhancing properties of MS or type 1 fimbriae [8, 9].
While the data presented in this manuscript are impor-
tant, it must be accepted that these experiments are per-
formed in a uniquely susceptible host. It will be important
in future work to marry observations of host susceptibil-
ity to those on bacterial virulence, which will hopefully
provide a better understanding of the pathogenesis of
urinary tract and renal infection.
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Reply from the Authors
We have read with great interest the letter to the Ed-
itor by Drs. Topley, Steadman, and Williams, who have
made excellent contributions to UTI research. Exper-
imental models of renal scarring is a classic topic that
has attracted investigators like Drs. Heptinstall, Hodson,
Kass, Roberts, Miller, Silverblatt, Ransley, and others. It
has long been accepted that the neutrophil is at the heart
of this problem, and a number of approaches have been
taken to modulate neutrophil function in animal models,
and to study the outcome of infection. Such approaches
include steroids, anti-inflammatory substances, and oxy-
gen radical scavengers. Our references were limited to
early investigators who formulated the basic questions
about susceptibility, and the contribution of reflux to scar-
ring, but we apologize if this was a poor choice. We agree
that a fuller survey of the field of renal scarring research
and experimental models would be useful and timely, but
a review format might be more suitable to fully discuss
the many relevant questions.
Our study concerned the role of host genetics and
demonstrated that a single gene deficiency may cause sus-
ceptibility to renal scarring in the mouse. It would have
been desirable to explore the influence of bacterial viru-
lence factors on the scarring process in a susceptible host,
but as fimbrial expression was not investigated, no discus-
sion of type 1 or P fimbriae was called for. We fully agree
that both the microbe and the host must be considered in
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order to better understand the pathogenesis of UTI and
renal scarring.
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Pharmacologic intervention to
prevent hemodialysis vascular
access thrombosis: The next
generation of treatment?
To the Editor: We would like to extend our congrat-
ulations to Dr. Masaki et al [1] for their excellent work.
Their delivery system offers great promise for evalua-
tion of drugs for the local use of antineoplastic drugs,
like paclitaxel in the prevention of intimal hyperpla-
sia in hemodialysis vascular accesses. We would like to
note, however, that there are many more classes of drugs
that might be beneficial other than strictly antiprolif-
erative drugs [2]. Drugs that improve endothelial func-
tion, antimigratory agents, as well as those that affect the
glycocalyx formation should be studied. Even among an-
tiproliferative drugs, we found that systemic adminis-
tration of non-antineoplastic antiproliferative drugs like
angiotensin-converting enzyme (ACE) inhibiters seemed
to be of most benefit in grafts (as Dr. Masaki notes),
while antineoplastic antiproliferative agents such as pa-
clitaxel seemed of most benefit in endogenous fistulas [3].
A more recent multicenter study [4] confirmed the bene-
ficial properties of ACE inhibiters. Certainly, if antineo-
plastic agents are proven to be the most beneficial agents
for survival in all vascular accesses, then a local delivery
system such as described by Dr. Masaki would be a great
advance; however, there is such potential myocardial ben-
efit to the systemic use of ACE inhibiters in patients with
ischemic heart disease or cardiomyopathies that systemic
administration may prove simpler, more beneficial, and
cost effective. Nevertheless, we see Dr. Masaki’s work as
a great advance, and we applaud their continued efforts.
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Locking hemodialysis
catheters with cefotaxime
instead of gentamicin to avoid
potential ototoxicity
To the Editor: McIntyre et al compared gentamicin
(5 mg/mL) and heparin-locked, tunneled hemodialysis
catheter group with that of catheter-restricted filling of
standard heparin (5000 IU/mL) alone; gentamicin-locked
group recorded significantly lower catheter-related
bloodstream infections catheter-related bloodstream
infections (CRBSI) episodes compared with heparin
group (0.3/1000 vs. 4/1000 catheter days, P = 0.02) [1].
Dogra et al observed significantly lower incidence of
CRBSI (0.03 vs. 0.42 per 100 catheter days, P = 0.003),
and considerably higher mean infection-free catheter sur-
vival in the gentamicin group (catheter-restricted filling
of gentamicin/citrate, 40 mg/mL, and 3.13% citrate) com-
pared with heparin group (282 days vs. 181 days, P =
0.002). However, authors cautioned to establish the safety
of ‘locked’ dose of gentamicin for ototoxicity before the
technique was adopted because predialysis plasma gen-
tamicin levels were significantly higher in patients ran-
domized to gentamicin group compared with heparin
group (2.8 mg/L vs. <0.2 mg/L, P = 0.008) [2].
In view of recently reported ototoxicity [3, 4] regardless
of reasonably lower amount of aminoglycosides being
used for ‘locking’ catheters, a prospective case-controlled
study was carried out at our center using cefotaxime
(10 mg/mL) in combination with heparin (5000 U/mL) to
examine the lock’s efficacy in the prevention of CRBSI
[5]. Cefotaxime was chosen because of its broad antimi-
crobial spectrum and lack of ototoxic potentials. The
‘lock’ was applied two/three times a week postdialy-
sis. A significant relative-risk reduction in the incidence
of HD-tunneled catheter thromboses (1.340–4.701, P =
0.003), CRBSI-incidence (3.086–6.430, P < 0.0001), and
CRBSI-related mortality (1.517–5.864, P < 0.001) was
